口服万科米辛在治疗Clostridioides difficile感染:波兰南部的一项单中心观察研究 (2016-2022),涉及528,887名住院患者
Anna Pałka1, Mateusz Gajda1, Norbert Kapczyński1
1Chair of Microbiology Medical Faculty, Jagiellonian University Medical College, 31-121 Kraków, Poland.
Antibiotics (Basel, Switzerland)
|February 27, 2026
概括
克洛斯特里迪奥伊德困难感染 (CDI) 发病率保持稳定,但在COVID-19大流行期间,医疗保健相关的CDI急剧增加. 范科米辛降低了死亡率,而组合治疗增加了复发.
科学领域:
- 传染性疾病 传染性疾病
- 流行病学 流行病学
- 抗微生物药物管理委员会
背景情况:
- 困难杆菌感染 (CDI) 构成了全球健康的重大威胁,特别是在资源有限的环境中.
- 了解CDI流行病学和治疗结果对于有效管理至关重要.
研究的目的:
- 在一大批住院患者中分析CDI的流行病学和治疗结果.
- 评估COVID-19大流行对医疗保健相关CDI (HA-CDI) 率的影响.
- 为了比较不同CDI治疗方案的有效性.
主要方法:
- 对波兰 (2016-2022) 单一中心的528,887名患者入院的回顾性分析.
- 鉴定和确认2341个CDI病例.
- 对不同疗法治疗结果的统计比较,包括死亡率和复发率.
主要成果:
- 整体CDI发病率为每1000例患者中4.32,老年和传染病单位的发病率最高.
- 在COVID-19大流行期间,HA-CDI病例显著增加,在2020年达到89.2%.
- 与甲尼达相比,万科米辛治疗的死亡率 (OR 0.73) 较低;组合治疗的复发率最高 (17%).
- 由于可用性问题,fidaxomicin的使用量很小 (0.4%).
- 总体而言,CDI的住院病例死亡率为22.5%.
结论:
- 随着COVID-19大流行,HA-CDI恶化,与抗生素使用增加有关.
- 需要加强抗微生物药物管理,并扩大对菲达克索米辛和贝兹洛托克苏马布等疗法的获取.
- 在治疗选择有限的环境中,万科米辛仍然是减少CDI相关死亡率的关键治疗选择.
相关概念视频
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
1.6K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
1.6K
Antimicrobial Effectiveness
1.4K
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
1.4K
Drugs for Treatment of Ulcerative Colitis in IBD
577
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
577
Drugs for Treatment of Diarrhea-Predominant IBS
798
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
798
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
577
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
577
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
604
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
604


